Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2006

View Archived Issues

Results of phase I and II studies of kinesin spindle protein inhibitors reported

Repeated CNTO-328 dosing feasible in patients with hematological malignancies

Long-lasting responses seen with AP-12009 in anaplastic astrocytoma and glioblastoma

Milataxel investigated in phase I and II trials in cancer patients

Studies detail CP-675206 dosing and activity in melanoma patients

Phase II liver cancer study to evaluate Avastin with chemoembolization

PhytoMedical Technologies and Iowa State University sign license agreement

Pfizer completes acquisition of fesoterodine rights from Schwarz Pharma

rEV-131 studied in pivotal Canadian trial for allergic rhinitis

Supernus signs agreement with United Therapeutics for UT-15C

New phase I study evaluates PXD-101 with cis-retinoic acid for solid tumors

Enrollment closing for phase II study of HyCAMP in metastatic colorectal cancer

Phase III studies of Puricase begin dosing

BiPar Sciences advances compounds after new financing

Series A financing to fund development of Danube's oral glaucoma therapy

Cobalis plans twin phase III studies for PreHistin

Norwegian hospitals to study GV-1001 for NSCLC

Orphan drug status for Surfaxin in prevention of bronchopulmonary dysplasia

European phase III study to begin for SP-01A in HIV

FAV-201 cleared to begin phase I/II study in CTCL

Enrollment completed in celgosivir phase IIb combination study in HCV

Locus submits IND for phase I study of lead compound LP-261

ARQ-501 studied with docetaxel and gemcitabine in refractory solid tumors

Sanctura XR reduces symptoms of overactive bladder

AN-0128 demonstrates activity in atopic dermatitis

Parion Sciences presents novel ENaC blocker as clinical candidate for CF

New PPARgamma modulators prepared and tested at Galderma

Pfizer report on novel NEP inhibitor for the treatment of FSAD

New agents with potential in the treatment of cancer imparted in recent patents

Hycamtin approved for use with cisplatin in cervical cancer

Promising preclinical data of S-40755 in the long-term control of glycemia in diabetic rodent models

Recombinant human fibroblast growth factor-21 demonstrates antidiabetic potential in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...